newsSeptember 23, 2026·TechCrunch AI
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Key Takeaways
- •The round valued the AI biotech at $2 billion
- •This story was reported by TechCrunch AI, covering developments in the news space.
- •AI advancements continue to reshape industries — read the full article on TechCrunch AI for complete coverage.
📖 Continue reading the full article:
Read Full Article on TechCrunch AI →
